Orthofix expands board with finance expert Vickie Capps

LEWISVILLE, Texas - Orthofix Medical Inc. (NASDAQ:OFIX), a global medical technology company with a market capitalization of $667 million, has announced the appointment of Vickie Capps to its Board of Directors, effective as of Monday. The addition of Capps, a seasoned finance professional and executive leader with extensive board experience, increases the board’s size to ten members.

With a background that includes a tenure as CFO of DJO Global, Inc. and board positions at several healthcare companies, Capps brings a robust blend of expertise to Orthofix’s board at a crucial time. According to InvestingPro data, while the company maintains strong liquidity with a current ratio of 2.57, it faces profitability challenges. Her current board roles include Amedisys, Inc., Janux Therapeutics, Inc., Enable Injections, Inc., and Breg, Inc., as well as her involvement with the San Diego State University Research Foundation and the Senior Advisory Board of Consonance Capital Partners.

Michael Finegan, Chairman of Orthofix, expressed confidence in Capps’s ability to contribute to the company’s growth and shareholder value, emphasizing her insights in global business operations, strategic development, and corporate finance. Capps herself conveyed her honor at joining the board and her anticipation to aid in the company’s strategic transformation.

Orthofix, headquartered in Lewisville, Texas, specializes in medical technologies that address musculoskeletal pathologies. The company’s product range includes spinal hardware, bone growth therapies, orthopedic solutions, biologics, and the 7D FLASH™ navigation system. InvestingPro analysis indicates the company has achieved 7% revenue growth over the last twelve months, though currently trades below its Fair Value. For deeper insights into Orthofix’s financial health and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports, available for over 1,400 US stocks.

This news is based on a press release statement and does not include any forward-looking statements. Orthofix routinely posts investor-relevant information on its website and encourages stakeholders to review these updates regularly.

In other recent news, Orthofix International reported its fourth-quarter earnings, revealing a revenue of $215.7 million, which represents a 7.6% increase year-over-year and exceeded the consensus estimate of $212.7 million. The company’s adjusted EBITDA also surpassed expectations, reaching $23.9 million compared to the projected $22.6 million, driven by strong performance in its Global Orthopedics segment and BioStim. Despite these positive results, Orthofix’s revenue guidance for fiscal year 2025 falls short of analyst projections, ranging between $818 million and $826 million, partly due to the discontinuation of certain product lines. BTIG maintained a Neutral rating for Orthofix, noting the potential for weak first-quarter sales in FY25 and a more gradual ramp-up in product contributions later in the year.

Meanwhile, Canaccord Genuity initiated coverage of Orthofix with a Buy rating and set a price target of $24.00. The firm expressed optimism about Orthofix’s strategic initiatives following its merger with SeaSpine and the establishment of a new management team. Canaccord highlighted the integration of Orthofix’s product offerings and personnel as a key factor supporting its long-range plan. The firm also emphasized Orthofix’s focus on innovation, cash generation, and margin expansion as drivers for future growth. Additionally, Canaccord pointed out that Orthofix’s current market valuation is below the average for comparable companies, reinforcing their Buy rating and confidence in the company’s strategic direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.